Detail Information of Xenobiotics
| General Information of Xenobiotics (ID: XEO00666) | ||||||
|---|---|---|---|---|---|---|
| Xenobiotics Name |
R-115866
|
|||||
| Xenobiotics Type |
Pharmaceutical Agent(s)
|
|||||
| Classification |
Drug in Phase 2 Clinical Trial
|
|||||
| Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=9799888"></iframe>
|
 |
||||
| 3D MOL | 2D MOL | |||||
| PubChem CID | ||||||
| DME(s) Modulated by This Xenobiotics | ||||||
| DME(s) Inhibited by This Xenobiotics | ||||||
| Retinoic acid 4-hydroxylase 26A1 (CYP26A1) | DME Info | Homo sapiens | [1] | |||
| Xenobiotics-DME Activity Data | ||||||
| Xenobiotics-DME Activity Data | Retinoic acid 4-hydroxylase 26A1 (CYP26A1) | DME Info | IC50 = 0.0051 microM | [1] | ||
| References | ||||||
| 1 | Development and characterization of novel and selective inhibitors of cytochrome P450 CYP26A1, the human liver retinoic acid hydroxylase. J Med Chem. 2016 Mar 24;59(6):2579-95. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.